Key Points
- Insider sale: EVP Marshall Urist sold 4,126 Royalty Pharma shares at an average price of $57.88, totaling $238,812.88. The transaction, executed under a pre-arranged Rule 10b5-1 plan, reduced his ownership by 50%.
- Financial performance and dividend: Royalty Pharma reported quarterly EPS of $1.32, exceeding estimates of $1.27, though revenue of $674.14 million fell short of the $758.93 million consensus. The company pays a quarterly dividend of $0.235 per share, or $0.94 annually, yielding about 1.6%.
- Analyst outlook remains positive: The stock has an average “Buy” rating and an average price target of $61.29, with targets from JPMorgan and Goldman Sachs reaching $62 and $66, respectively.
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 4,126 shares of the company's stock in a transaction on Monday, September 28th. The shares were sold at an average price of $57.88, for a total transaction of $238,812.88. Following the transaction, the executive vice president owned 4,126 shares of the company's stock, valued at approximately $238,812.88. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Royalty Pharma Stock Performance
NASDAQ RPRX opened at $58.36 on Thursday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. The firm has a market capitalization of $33.56 billion, a price-to-earnings ratio of 40.25, a P/E/G ratio of 1.37 and a beta of 0.44. The company's fifty day moving average is $59.58 and its two-hundred day moving average is $54.80. Royalty Pharma PLC has a 52-week low of $35.23 and a 52-week high of $64.38.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.05. The company had revenue of $674.14 million for the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. Equities research analysts forecast that Royalty Pharma PLC will post 5.32 EPS for the current year.
Royalty Pharma Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Friday, August 14th were given a dividend of $0.2350 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma's dividend payout ratio (DPR) is 64.83%.
Analysts Set New Price Targets
Several equities analysts have commented on RPRX shares. JPMorgan Chase & Co. upped their price target on Royalty Pharma from $58.00 to $62.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Wall Street Zen cut Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 26th. Bank of America restated a "buy" rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Weiss Ratings raised Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a research report on Monday, September 14th. Finally, The Goldman Sachs Group reiterated a "buy" rating and set a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $61.29.
View Our Latest Analysis on RPRX
Institutional Investors Weigh In On Royalty Pharma
Several large investors have recently made changes to their positions in RPRX. Phillips Wealth Planners LLC lifted its holdings in Royalty Pharma by 1.9% during the 4th quarter. Phillips Wealth Planners LLC now owns 13,113 shares of the biopharmaceutical company's stock valued at $521,000 after purchasing an additional 242 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in shares of Royalty Pharma by 3.4% during the first quarter. Glenmede Trust Co. NA now owns 7,812 shares of the biopharmaceutical company's stock worth $375,000 after buying an additional 254 shares in the last quarter. Bessemer Group Inc. increased its holdings in shares of Royalty Pharma by 34.7% during the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 282 shares in the last quarter. CoreCap Advisors LLC raised its stake in shares of Royalty Pharma by 89.2% in the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 413 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Royalty Pharma by 173.4% in the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 437 shares during the last quarter. Institutional investors own 54.35% of the company's stock.
Royalty Pharma Company Profile
(
Get Free Report)
Royalty Pharma plc is a biopharmaceutical royalty acquisition company that provides funding to life sciences companies in exchange for rights to future payments associated with approved or development-stage medicines. Its business model gives biotechnology and pharmaceutical companies access to capital while allowing Royalty Pharma to participate in the commercial success of therapies without directly developing or marketing them.
The company invests in royalties and other economic interests tied to a broad range of biopharmaceutical products, including treatments for cancer, rare diseases, immune disorders, diabetes and other chronic conditions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
